Is UNII-PR834Q503T Safe in Breastfeeding

I am a breastfeeding mother and i want to know if it is safe to use UNII-PR834Q503T? Is UNII-PR834Q503T safe for nursing mother and child? Does UNII-PR834Q503T extracts into breast milk? Does UNII-PR834Q503T has any long term or short term side effects on infants? Can UNII-PR834Q503T influence milk supply or can UNII-PR834Q503T decrease milk supply in lactating mothers?

• DrLact safety Score for UNII-PR834Q503T is 5 out of 8 which is considered Unsafe as per our analyses.
• A safety Score of 5 indicates that usage of UNII-PR834Q503T may cause serious side effects in breastfed baby.
• Our study of different scientific research indicates that UNII-PR834Q503T may cause moderate to high side effects or may affect milk supply in lactating mother.
• Our suggestion is to use safer alternate options rather than using UNII-PR834Q503T .
• It is recommended to evaluate the advantage of not breastfeeding while using UNII-PR834Q503T Vs not using UNII-PR834Q503T And continue breastfeeding.
• While using UNII-PR834Q503T Its must to monitor child for possible reactions. It is also important to understand that side effects vary largely based on age of breastfed child and time of medication in addition to dosage.
• Score calculated using the DrLact safety Version 1.2 model, this score ranges from 0 to 8 and measures overall safety of drug in lactation. Scores are primarily calculated using publicly available case studies, research papers, other scientific journals and publically available data.

Ergot derivative alkaloid. It may inhibit prolactin secretion. It is used together with other substances (e.g. caffeine, which is a cause of anxiety). Multiple drug association is not recommended. On latest update relevant data on breastfeeding was not found. Sumatriptan which is a drug with well known low excretion into breast milk should be an alternative treatment for Migraine.

Because there is limited published experience with UNII-PR834Q503T during breastfeeding and it might cause adverse effects in the infant, most authorities consider UNII-PR834Q503T to be undesirable to use during nursing.[1][2]

A study in which UNII-PR834Q503T was administered to mothers of newborns immediately postpartum in a dose of 1 mg 3 times daily for 6 days found no effect on weight gain in the breastfed infants.[3] Milk intake, and therefore infant dosage, might have been minimal during the first few days before the mothers' milk came in fully.

Thirty women who delivered fullterm infants received a single intramuscular dose of methylergonovine 0.2 mg after delivery, followed by oral UNII-PR834Q503T 1 mg 3 times daily for 6 days. Compared to 28 women who delivered fullterm infants and received no ergot derivatives, there was no difference in the milk production, as measured by weight differences before and after nursing, between the 2 groups during the first 6 days postpartum.[3]